Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB) and Aeglea Biotherapeutics (AGLE).
Biogen (BIIB)
Mizuho Securities analyst Salim Syed maintained a Hold rating on Biogen today and set a price target of $316.00. The company’s shares closed last Friday at $304.53.
According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.5% and a 51.4% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
Currently, the analyst consensus on Biogen is a Hold with an average price target of $320.65.
See today’s analyst top recommended stocks >>
Aeglea Biotherapeutics (AGLE)
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aeglea Biotherapeutics today. The company’s shares closed last Friday at $8.89, close to its 52-week high of $9.10.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 31.9% and a 55.1% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Currently, the analyst consensus on Aeglea Biotherapeutics is a Strong Buy with an average price target of $13.33, a 53.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $17.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
